XVIVO’s Kidney Assist Transport Receives 510(k) Clearance by US FDA, Which Is XVIVO’s First Regulatory Cleared Product for Abdominal Transplantation in the US 
LevelJump Announces $2.5 Million Non-Brokered Private Placement 
Cybeats Joins OASIS Open; Congratulates Cybeats Advisor, Duncan Sparrell, on Winning OASIS Distinguished Contributor Award 
iCRYO Partners With 24 Hour Fitness
Fitness Industry Giant And Recovery Leader Come Together To Provide Full Body Wellness To 24 Hour Fitness Members HOUSTON, TEXAS,...
Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet
CHENGDU, China, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing...
Extendicare Announces Timing of 2021 Fourth Quarter Results and Year End Results and Conference Call
MARKHAM, Ontario, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it...
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking...
Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today
SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty...
Kraig Biocraft Laboratories Closes Additional Funding Agreement
Robust financial strength positions Company to deploy Impact CapitalANN ARBOR, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories,...
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021
NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company...
Circulating Tumor Cell (CTC) Isolation with TellDx Technology Could Inform Personalized Drug Treatment in Prostate Cancer
-- Single-cell proteomics can elucidate kinase activity in prostate cancer models -- -- Kinase activity in bone metastases and epithelial...
Rapid Micro Biosystems Appoints Michael Beaulieu as Vice President, Investor Relations and Corporate Communications
LOWELL, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 2, 2022
BILLERICA, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business...